ѻý

End of Life and COVID-19; DCIS Doubles Cancer Risk; Training for 'Bad News'

<ѻý class="mpt-content-deck">— News, features, and commentary about cancer-related issues
MedpageToday
Cancer cells with OncoBreak in the center.

Cancer patients and survivors ponder in the era of COVID-19. (STAT)

Patients with associated with DNA repair defects lived 10 months longer when treated with platinum-based chemotherapy as compared with patients whose cancers did not have the defects. (American Association for Cancer Research)

Takeda Pharmaceuticals for first-line treatment of metastatic ALK-positive non-small cell lung cancer (NSCLC).

The FDA also approved nivolumab (Opdivo) plus ipilimumab (Yervoy) in combination with a short course of platinum-based chemotherapy as for certain patients with metastatic or recurrent NSCLC, Bristol-Myers Squibb announced.

Ductal carcinoma in situ of developing invasive breast cancer later on. (The BMJ)

The American Society of Clinical Oncology published a (or wasting syndrome) in patients with advanced cancer.

Pregnancy before age 25 appears to to reduce the risk of breast cancer. (Cold Spring Harbor Laboratory)

Within a few months of taking up vaping, users' mouths become associated with multiple diseases, including cancer. (Ohio State University)

A to one of the giants of breast cancer research. (Journal of Clinical Oncology)

Cancer specialists in how to provide palliative care and to deliver "bad news" to patients and families. (Johns Hopkins Kimmel Cancer Center)

If you think you've been seeing from Big Pharma, you're not imagining things. (FiercePharma)

More evidence of a in ethnic minority men. (American Association for Cancer Research)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined ѻý in 2007.